Smith & Wesson (NASDAQ:SWBI) struggles with weak post-pandemic demand alongside inflationary pressures and declining consumer sentiment. Despite ongoing claims that new product launches will counteract the sluggish industry landscape, both sales and profitability continue to decline.
Analysts suggest that while there may be a potential for recovery with slight improvements in fiscal results, shareholders should brace for possible modest price pullbacks before considering investment. As the company prepares for upcoming quarterly results, investors remain cautious about timing their entries into the market.
Read full story at seekingalpha.com
